Thank you to everyone who joined
our campaign calling for Australians to get equal and affordable access to
Avastin (bevacizumab). The response to our campaign has been hugely positive,
with dozens of members of the Australian brain cancer community joining us in
making a submission to the Pharmaceutical Benefits Advisory Committee (PBAC)
before the deadline of 13 February. Now we enter the next phase, and we need
your help to keep the pressure on decision-makers.
Submissions to the PBAC are not publicly available, but if you would like to lend your voice to our ongoing campaign in public, just like Lyn Phelan, we want to hear from you. We want to share your Avastin submissions on Cure Brain Cancer Foundation’s social media and website, ensuring our combined voice is too compelling for the PBAC and Federal Government to ignore. Please email us at email@example.com if you’d like to be involved in this important next phase.
"Relieving some of the financial strain experienced by patients and their families and potentially offering a better quality of life at a time when health is declining would provide a huge relief to all concerned."
Read GBM survivor Lyn Phelan's Avastin submission to the PBAC.
The ultimate decision for which drugs to list on the PBAC sits with the Health Minister, Greg Hunt MP. You can email him directly, outlining your thoughts on why Avastin should be listed on the PBS at this website.
Help fund vital brain cancer research